Timber Pharmaceuticals Analyst Ratings
Timber Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2022 | 1264.26% | HC Wainwright & Co. | $1.5 → $1 | Maintains | Buy |
| 08/29/2022 | 1264.26% | HC Wainwright & Co. | $1.5 → $1 | Maintains | Buy |
| 05/02/2022 | 1946.38% | HC Wainwright & Co. | $2 → $1.5 | Maintains | Buy |
| 03/31/2022 | 2628.51% | HC Wainwright & Co. | → $2 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 2022 年 10 月 26 日 | 1264.26% | HC Wainwright & Co. | 1.5 美元 → 1 美元 | 维护 | 买 |
| 08/29/2022 | 1264.26% | HC Wainwright & Co. | 1.5 美元 → 1 美元 | 维护 | 买 |
| 05/02/2022 | 1946.38% | HC Wainwright & Co. | $2 → 1.5 美元 | 维护 | 买 |
| 03/31/2022 | 2628.51% | HC Wainwright & Co. | → 2 美元 | 启动覆盖范围开启 | → 购买 |
Timber Pharmaceuticals Questions & Answers
木材药品问题与解答
The latest price target for Timber Pharmaceuticals (AMEX: TMBR) was reported by HC Wainwright & Co. on October 26, 2022. The analyst firm set a price target for $1.00 expecting TMBR to rise to within 12 months (a possible 1264.26% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年10月26日公布了木材制药（美国证券交易所股票代码：TMBR）的最新目标股价。该分析公司将目标股价定为1.00美元，预计TMBR将在12个月内升至12个月内（可能上涨1264.26％）。去年有4家分析公司公布了评级。
The latest analyst rating for Timber Pharmaceuticals (AMEX: TMBR) was provided by HC Wainwright & Co., and Timber Pharmaceuticals maintained their buy rating.
木材制药公司（美国证券交易所股票代码：TMBR）的最新分析师评级由HC Wainwright & Co. 提供，Timber Pharmicals维持买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Timber Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Timber Pharmaceuticals was filed on October 26, 2022 so you should expect the next rating to be made available sometime around October 26, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Timber Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Timber Pharmicals的最新评级是在2022年10月26日发布的，因此您应该预计下一个评级将在2023年10月26日左右公布。
While ratings are subjective and will change, the latest Timber Pharmaceuticals (TMBR) rating was a maintained with a price target of $1.50 to $1.00. The current price Timber Pharmaceuticals (TMBR) is trading at is $0.07, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的木材制药公司（TMBR）评级维持不变，目标股价为1.50美元至1.00美元。木材制药（TMBR）目前的交易价格为0.07美元，超出了分析师的预期区间。